Physician profile
Ali Kassamali
NPI 1003102898
$8,938.44
in general payments reported to CMS, 2019-2025
37 companies · $37.50 in 2025
The $37.50 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $1,470 · 2021: $465 · 2022: $2,509 · 2023: $601 · 2024: $1,881 · 2025: $37.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,263.60 | 2019-2024 | Senza |
| Boston Scientific Corporation | $1,448.21 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $1,088.42 | 2019-2023 | Proclaim |
| Relievant Medsystems, INC. | $973.21 | 2022 | |
| Medtronic, INC. | $750.64 | 2022-2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $453.64 | 2019-2021 | |
| Painteq LLC | $417.14 | 2021-2024 | Painteq |
| Forte Bio-Pharma LLC | $251.30 | 2020-2024 | Prolate, Nalocet |
| Stimwave Technologies Incorporated | $234.26 | 2019-2022 | |
| Curonix LLC | $169.83 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $159.92 | 2019-2023 | Belbuca, Xtampza |
| Eisai INC. | $60.31 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $57.31 | 2023-2024 | Horizant, Horizant |
| Pfizer INC. | $52.01 | 2019-2021 | |
| Tersera Therapeutics LLC | $46.42 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $44.01 | 2019-2022 | |
| Medtronic USA, INC. | $42.43 | 2019-2020 | |
| Assertio Therapeutics, INC. | $38.14 | 2019-2020 | |
| Pacira Therapeutics, INC. | $36.16 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $34.39 | 2019 | |
| Biotronik Nro, INC. | $31.31 | 2023 | Biotronik |
| Electronic Waveform Lab, INC. | $28.16 | 2019 | |
| Radius Health, INC. | $26.73 | 2019 | |
| Biodelivery Sciences International, INC. | $26.10 | 2019-2020 | |
| Zyla Life Sciences, INC. | $25.56 | 2019 | |
| Siemens Medical Solutions USA, INC. | $19.86 | 2025 | Acuson Juniper Diagnostic Ultrasound System |
| Upsher-Smith Laboratories LLC | $19.01 | 2019 | |
| Grt US Holding, INC. | $17.86 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.61 | 2021 | |
| Lilly USA, LLC | $15.33 | 2019 | |
| Vertos Medical, INC. | $14.86 | 2024 | Mild Device Kit |
| Novartis Pharmaceuticals Corporation | $14.78 | 2019 | |
| Saluda Medical Americas, INC. | $13.94 | 2023 | Evoke Scs |
| Redhill Biopharma INC. | $13.13 | 2021 | |
| Sentynl Therapeutics, INC. | $12.48 | 2019 | |
| Nalu Medical, INC. | $12.37 | 2020 | |
| Spr Therapeutics, INC | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Kassamali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.